Myocardial infarction during factor IX infusion in hemophilia B: Case report and review of the literature

Syed Muhammad Najaf; Amyn Malik; Ata Ur Rehman Quraishi; Khawar Kazmi; Ghulam Nabi Kakepoto

doi:10.1007/s00277-004-0900-9

Myocardial infarction during factor IX infusion in hemophilia B: Case report and review of the literature

Syed Muhammad Najaf, Amyn Malik, Ata Ur Rehman Quraishi, Khawar Kazmi, Ghulam Nabi Kakepoto

Department of Medicine, Medical College, Pakistan

Research output: Contribution to journal › Review article › peer-review

5 Citations (Scopus)

Abstract

There are very few reports in the literature of acute myocardial infarction (MI) occurring during infusion of factor concentrates, particularly cryosupernatant in patients with hemophilia B. We describe a case of a 61-year-old man with hemophilia B who suffered an acute MI while receiving cryosupernatant infusion as factor replacement therapy. Cryosupernatant is rich in coagulation factor IX and contains low levels of fibrinogen and von Willebrand's factor. Factor IX and other factors present in cryosupernatant can possibly become activated during the manufacturing process causing thrombus formation in patients who are prone to it.

Original language	English (UK)
Pages (from-to)	604-607
Number of pages	4
Journal	Annals of Hematology
Volume	83
Issue number	9
DOIs	https://doi.org/10.1007/s00277-004-0900-9
Publication status	Published - Sept 2004

Keywords

Cryosupernatant
Hemophilia B
Myocardial infarction

Access to Document

10.1007/s00277-004-0900-9

Cite this

@article{594c8351cc9a43ba8964b47acfdeae8c,

title = "Myocardial infarction during factor IX infusion in hemophilia B: Case report and review of the literature",

abstract = "There are very few reports in the literature of acute myocardial infarction (MI) occurring during infusion of factor concentrates, particularly cryosupernatant in patients with hemophilia B. We describe a case of a 61-year-old man with hemophilia B who suffered an acute MI while receiving cryosupernatant infusion as factor replacement therapy. Cryosupernatant is rich in coagulation factor IX and contains low levels of fibrinogen and von Willebrand's factor. Factor IX and other factors present in cryosupernatant can possibly become activated during the manufacturing process causing thrombus formation in patients who are prone to it.",

keywords = "Cryosupernatant, Hemophilia B, Myocardial infarction",

author = "Najaf, \{Syed Muhammad\} and Amyn Malik and Quraishi, \{Ata Ur Rehman\} and Khawar Kazmi and Kakepoto, \{Ghulam Nabi\}",

year = "2004",

month = sep,

doi = "10.1007/s00277-004-0900-9",

language = "English (UK)",

volume = "83",

pages = "604--607",

journal = "Annals of Hematology",

issn = "0939-5555",

publisher = "Springer Science and Business Media Deutschland GmbH",

number = "9",

}

TY - JOUR

T1 - Myocardial infarction during factor IX infusion in hemophilia B

T2 - Case report and review of the literature

AU - Najaf, Syed Muhammad

AU - Malik, Amyn

AU - Quraishi, Ata Ur Rehman

AU - Kazmi, Khawar

AU - Kakepoto, Ghulam Nabi

PY - 2004/9

Y1 - 2004/9

N2 - There are very few reports in the literature of acute myocardial infarction (MI) occurring during infusion of factor concentrates, particularly cryosupernatant in patients with hemophilia B. We describe a case of a 61-year-old man with hemophilia B who suffered an acute MI while receiving cryosupernatant infusion as factor replacement therapy. Cryosupernatant is rich in coagulation factor IX and contains low levels of fibrinogen and von Willebrand's factor. Factor IX and other factors present in cryosupernatant can possibly become activated during the manufacturing process causing thrombus formation in patients who are prone to it.

AB - There are very few reports in the literature of acute myocardial infarction (MI) occurring during infusion of factor concentrates, particularly cryosupernatant in patients with hemophilia B. We describe a case of a 61-year-old man with hemophilia B who suffered an acute MI while receiving cryosupernatant infusion as factor replacement therapy. Cryosupernatant is rich in coagulation factor IX and contains low levels of fibrinogen and von Willebrand's factor. Factor IX and other factors present in cryosupernatant can possibly become activated during the manufacturing process causing thrombus formation in patients who are prone to it.

KW - Cryosupernatant

KW - Hemophilia B

KW - Myocardial infarction

UR - https://www.scopus.com/pages/publications/4444267640

U2 - 10.1007/s00277-004-0900-9

DO - 10.1007/s00277-004-0900-9

M3 - Review article

C2 - 15205916

AN - SCOPUS:4444267640

SN - 0939-5555

VL - 83

SP - 604

EP - 607

JO - Annals of Hematology

JF - Annals of Hematology

IS - 9

ER -

Myocardial infarction during factor IX infusion in hemophilia B: Case report and review of the literature

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this